Johnson & Johnson $JNJ Shares Sold by Viewpoint Capital Management LLC

Viewpoint Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,339 shares of the company’s stock after selling 97 shares during the quarter. Johnson & Johnson makes up about 1.1% of Viewpoint Capital Management LLC’s holdings, making the stock its 27th largest position. Viewpoint Capital Management LLC’s holdings in Johnson & Johnson were worth $2,190,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in JNJ. Brighton Jones LLC boosted its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the 1st quarter worth $218,000. GAMMA Investing LLC grew its position in Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after purchasing an additional 14,118 shares during the last quarter. Crescent Sterling Ltd. increased its stake in Johnson & Johnson by 1.7% in the first quarter. Crescent Sterling Ltd. now owns 23,635 shares of the company’s stock valued at $3,920,000 after purchasing an additional 396 shares during the period. Finally, Sonora Investment Management Group LLC boosted its stake in shares of Johnson & Johnson by 2.5% during the first quarter. Sonora Investment Management Group LLC now owns 107,836 shares of the company’s stock worth $17,884,000 after buying an additional 2,666 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $189.75 on Thursday. The company has a market capitalization of $456.98 billion, a PE ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $190.22. The company has a 50-day simple moving average of $177.49 and a 200-day simple moving average of $163.37. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the business posted $2.82 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 3rd. The Goldman Sachs Group upped their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Finally, Bank of America lifted their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.